Insider · CIK 0001704754
Christine S Breves
director
Files at MPLX (MPLX LP), SLVM (Sylvamo Corp), RXO (RXO, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | MPLX MPLX LP | AGrant or award Common Units (Limited Partner Interests) | +145 | $0.00 | $0 | 8,301 | Feb 18, 2025 |
| Jan 24, 2025 | SLVM Sylvamo Corp | AGrant or award Deferred Stock Unitsderivative | +31 | $81.13 | $2,499 | 251 | Jan 28, 2025 |
| Jan 24, 2025 | SLVM Sylvamo Corp | AGrant or award Dividend Equivalent Unitsderivative | +10 | $81.13 | $809 | 103 | Jan 28, 2025 |
| Jan 2, 2025 | MPLX MPLX LP | AGrant or award Common Units (Limited Partner Interests) | +642 | $0.00 | $0 | 8,156 | Jan 6, 2025 |
| Jan 2, 2025 | RXO RXO, Inc. | MOption exercise Common Stock | +8,045 | $0.00 | $0 | 26,530 | Jan 6, 2025 |
| Jan 2, 2025 | RXO RXO, Inc. | AGrant or award Restricted Stock Unitderivative | +7,745 | $0.00 | $0 | 15,790 | Jan 6, 2025 |
| Jan 2, 2025 | RXO RXO, Inc. | MOption exercise Restricted Stock Unitderivative | -8,045 | $0.00 | $0 | 7,745 | Jan 6, 2025 |
| Nov 15, 2024 | MPLX MPLX LP | AGrant or award Common Units (Limited Partner Interests) | +150 | $0.00 | $0 | 7,513 | Nov 19, 2024 |
| Oct 17, 2024 | SLVM Sylvamo Corp | AGrant or award Deferred Stock Unitsderivative | +29 | $86.97 | $2,486 | 220 | Oct 21, 2024 |
| Oct 17, 2024 | SLVM Sylvamo Corp | AGrant or award Dividend Equivalent Unitsderivative | +9 | $86.97 | $805 | 93 | Oct 21, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.